The 340B program is increasing healthcare costs for employers and driving hospital consolidation, argued panelists at a recent healthcare purchaser [...] …
Category: Trade Association
Johnson & Johnson’s (J&J’s) lawsuit challenging the federal government’s opposition to 340B rebates will test whether the Trump administration is [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Pharmaceutical Research and Manufacturers of America (PhRMA) expressed “serious concerns” with the federal government’s opposition to Johnson & Johnson’s (J&J’s) [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Multiple 340B provider groups have applauded the federal government for threatening “strong” enforcement actions that led Johnson & Johnson (J&J) [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The drug industry and 340B program advocates offered mixed reactions Monday to a key senator’s latest inquiries into drugmakers’ contract [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Two major hospital advocacy groups are urging the federal agency that oversees the 340B program to “take immediate enforcement action” [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
In a move that would fundamentally alter the 340B program, pharmaceutical giant Johnson & Johnson (J&J) told hospitals this morning [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Trade groups representing pharmacists and 340B health systems have jointly released model state legislation that would prohibit drugmaker 340B contract [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Two weeks after publishing an opinion piece that called for increased 340B program oversight and provider transparency, JAMA issued a [...] …
